DMAC News and Press, DiaMedica Therapeutics Inc. From 03/14/22

DiaMedica Therapeutics press release (NASDAQ:DMAC): FY GAAP EPS of -$0.65 beats by $0.08. As of December 31, 2021, DiaMedica had cash, cash equivalents and marketable securities of $45.1 million, working capital of $43.9 million and shareholders’ equity of $44.0 million, compared to $2...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its fourth quarter 2021 financial results will be released after the markets close on Monday...

Leadership Team Continues to Expand with Addition of Veteran Genentech Executive DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 Internat...

Executive with Extensive Track Record in Neurology and Rare Disease Drug Development DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced to...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company is participating in the LifeSci Partners 11 th Annual Corporate Access Event...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, President and CEO, will participate in a fireside chat at the upcoming Piper San...

DiaMedica Therapeutics Inc. (DMAC) Q3 2021 Earnings Conference Call November 11, 2021 08:00 AM ET Company Participants Rick Pauls - President, CEO & Director Scott Kellen - CFO & Company Secretary Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Thomas Flaten - Lak...

Conference Call and Webcast November 11 at 8:00 am Eastern Time / 7:00 am Central Time First Patient Dosed in Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke FDA Ac...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 12th Annual Craig-Hallum Alpha Select Conference being held ...